Researchers at the University of La Rioja (UR) and Encore Lab have developed a mathematical model to estimate one-year survival probability in advanced pancreatic cancer patients using a simple blood test. This innovation, from Rocío del Campo Pedrosa’s doctoral thesis—the first Industrial Doctorate at UR—analyzes three common biomarkers: GGT, LDH, and monocytes.
Key Features and Impact
- Provides oncologists with objective data (74% accuracy) to personalize treatments for locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
- Identifies a novel prognostic biomarker: hemoglobin-to-monocyte ratio, outperforming traditional markers.
- Developed collaboratively with CIBIR and Hospital San Pedro, combining data science with clinical insights for real-world application.
This tool exemplifies machine learning in precision medicine, with potential as user-friendly software.
Learn More
Explore the Coverage:
UR, Encore Lab y cáncer de páncreas (Diario La Rioja)
Salud: Investigación UR (Nuevecuatrouno)
Herramienta matemática (Nova Ciencia)
Nueva herramienta (Infosalus)
Nueva herramienta pronóstica (Europa Press La Rioja)
Herramienta matemática (Rioja2)
Rocío del Campo Pedrosa (COPE)